1. Novel green synthesis of silver nanoparticles mediated by Curcumae kwangsiensis for anti-lung cancer activities: a preclinical trial study
- Author
-
Zhihong Liu, Zhuohong Zhang, Xiaomei Du, Ying Liu, Abdullah Alarfaj, Abdurahman Hirad, Siddique Akber Ansari, and Zhiguo Zhang
- Subjects
silver nanoparticles ,curcumae kwangsiensis folium ,antioxidant ,cytotoxicity ,anti-human lung cancer ,Medicine - Abstract
Introduction The present work describes the green synthesis and characterization and cytotoxicity, antioxidant, and anti-human lung cancer activities of silver nanoparticles containing Curcumae kwangsiensis folium leaf aqueous extract. Material and methods Ag nanoparticles were produced by mixing the AgNO3 solution with aqueous C. kwangsiensis folium leaf extract. Characterization of Ag nanoparticles was done by FE-SEM, FT-IR, TEM, and UV-Vis. FE-SEM and TEM images revealed an average diameter of 15-21 nm for the nanoparticles. MTT assay was used on common human lung cancer cell lines, i.e., lung well-differentiated bronchogenic adenocarcinoma (HLC-1), lung moderately differentiated adenocarcinoma (LC-2/ad), and lung poorly differentiated adenocarcinoma (PC-14) cell lines, to survey the cytotoxicity and anti-human lung cancer effects of Ag nanoparticles. Results They had very low cell viability and high anti-human lung cancer activities dose-dependently against HLC-1, LC-2/ad, and PC-14 cell lines without any cytotoxicity towards the normal cell line (HUVEC). The IC50 values of Ag nanoparticles were 249, 187, and 152 µg/ml against HLC-1, LC-2/ad, and PC-14 cell lines, respectively. The best results of cytotoxicity and anti-human lung cancer properties were seen at the concentration of 1000 µg/ml. Ag nanoparticles inhibited half of the DPPH molecules in the concentration of 135 µg/ml. Maybe significant anti-human lung cancer potentials of Ag nanoparticles synthesized by C. kwangsiensis folium leaf aqueous extract against common human lung cancer cell lines are linked to their antioxidant activities. Conclusions After confirming the above results in the clinical trial research, this formulation can be administered to treat human lung cancers in humans.
- Published
- 2021
- Full Text
- View/download PDF